Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:BIVI NASDAQ:BLUE NASDAQ:KLRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.62+1.9%$1.58$1.03▼$8.64$50.54M-0.32521,813 shs340,884 shsBIVIBioVie$8.05+10.1%$10.09$6.20▼$75.00$14.97M0.73186,749 shs94,277 shsBLUEbluebird bio$4.97$4.78$3.20▼$27.40$48.67M0.27447,328 shsN/AKLRSKalaris Therapeutics$2.42-1.6%$0.00$2.28▼$24.15$45.26M0.4839,413 shs203,569 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+4.95%+0.63%+3.92%+31.40%-78.51%BIVIBioVie+4.58%-9.19%-32.94%-13.06%+62.55%BLUEbluebird bio0.00%0.00%0.00%+20.05%-81.59%KLRSKalaris Therapeutics+2.50%-3.53%-7.87%+245,999,900.00%+245,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals2.807 of 5 stars3.45.00.00.02.90.00.6BIVIBioVie1.0665 of 5 stars0.04.00.00.03.60.00.6BLUEbluebird bio1.585 of 5 stars3.10.00.00.00.01.71.3KLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00146.91% UpsideBIVIBioVie 4.00Strong BuyN/AN/ABLUEbluebird bio 2.25Hold$44.60797.38% UpsideKLRSKalaris Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIVI, ATNM, KLRS, and BLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ABIVIBioVieN/AN/AN/AN/A$25.35 per shareN/ABLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14KLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/ABIVIBioVie-$32.12M-$79.10N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/ALatest BIVI, ATNM, KLRS, and BLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2025BLUEbluebird bio-$1.91N/AN/AN/A$45.60 millionN/A5/12/2025Q3 2025BIVIBioVie-$3.20-$1.50+$1.70-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25BIVIBioVieN/A9.319.31BLUEbluebird bio0.370.510.33KLRSKalaris TherapeuticsN/A14.3114.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%BIVIBioVie4.59%BLUEbluebird bio87.43%KLRSKalaris Therapeutics66.05%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%BIVIBioVie2.39%BLUEbluebird bio1.40%KLRSKalaris Therapeutics74.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableBIVIBioVie101.86 million1.82 millionNo DataBLUEbluebird bio5209.79 million9.59 millionOptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/ABIVI, ATNM, KLRS, and BLUE HeadlinesRecent News About These CompaniesBernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. SecuritiesJune 5, 2025 | globenewswire.comKalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceJune 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, ATNM, KLRS, and BLUE Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.62 +0.03 (+1.89%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.05 (+3.40%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.BioVie NASDAQ:BIVI$8.05 +0.74 (+10.12%) Closing price 04:00 PM EasternExtended Trading$8.13 +0.08 (+0.99%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$2.42 -0.04 (-1.63%) As of 04:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
